Kinesin Spindle Protein Inhibition in Translational Research

Bayalagama Nyamaa, Hyoung Kyu Kim, Yu Jeong Jeong, In-Sung Song, Jin Han

National Research Laboratory for Mitochondrial Signaling, Department of Physiology, College of Medicine, Department of Health Sciences and Technology, Cardiovascular and Metabolic Disease Center, Inje University, Busan, Korea

The kinesin superfamily is a class of motor proteins moving along microtubule filaments and playing essential roles in mitosis of eukaryotic cells. In the cancer biology, mitotic activity is an essential factor for development and metastasis of various cancers. Therefore, the inhibition of kinesin activity is suggested as an alternative cancer therapy. Accumulated clinical evidences have proved the potency of kinesin inhibitors in cancer treatments. In this review, we provided an overview of kinesins that play a critical role in the pathophysiology of various cancers and described the beneficial vs. side effects of their inhibitors that have been tested in both basic science and clinical studies.

Key Words: Kinesin, Kinesin spindle protein, KSP inhibitor, Cancer

INTRODUCTION

Cancer is a gene-associated disease with abnormal and unregulated cell proliferation. Normal cell growth needs a balance between the self-activities of those genes that control cell proliferation. It also depends on the activities of genes that signal when damaged cells should undergo cell death. In case of healthy cells, few thousand of genes activity control the process of cell division. The cell division means to divide into two or more daughter cells, that daughter cell retains with a full set of chromosomes. Agents targeting cell division could induce abnormal mitosis in tumor cells, may lead to mitotic arrest and cell death. The Kinesin superfamily is a protein belongs to a class of motor proteins, that kinesins move along microtubule filaments, and are powered by the hydrolysis of adenosin triphosphate (ATP). The Kinesin plays an essential roles in mitosis of eukaryotic cells, such as mitotic spindle function, targets in the anti-mitotic cancer therapeutics.

Some that have already been studied in phase I/II clinical trials have shown anti-proliferative effects without causing significant neuropathy. Because kinesin spindle protein (KSP) inhibitors do not target microtubules, they are more specific and associated with lesser side effects then anti-microtubule drugs. In this review, we will provide an overview of kinesins that play a critical role in the pathophysiology of various cancers and describe the beneficial vs. side effects of their inhibitors that have been tested in both basic science and clinical studies.
I. KINESINS

Kinesin was discovered in 1985 from nervous tissue. Kinesins generate directed mechanical force by hydrolyzing ATP and move along microtubule filaments from the minus end (oriented toward the nucleus) to the plus end (oriented toward the cell periphery). Kinesins play a massive role in the separation of centrosomes, the assembly of bipolar spindles, and the faithful segregation of chromosomes into daughter cells during prophase, prometaphase, metaphase, anaphase, and telophase. Kinesins also serve an important role in microtubule polymer dynamics, and signal transduction. Mitotic kinesins are cytoskeletal motor proteins that perform special and essential roles in cell proliferation. These proteins transport cellular components including genetic materials along microtubule. So KSP inhibitors specifically disrupt cell division, leaving other cytoskeletal processes unaffected, and therefore represent a potentially safer more effective approach to the treatment of cancer.

Around 650 kinesin superfamily discovered in all eukaryotic organisms. The Kinesin motor proteins often participate in cell- and tissue specific functions, such as mitosis or meiosis. Over than 40 kinesin proteins, named kinesin-1 through kinesin-14. Kinesin-1,3,4,12 and kinesin-14 are transport of organelles, whereas kinesin-1, kinesin-4,5,6,7,8,10,12 and kinesin-13 participated in cell mitosis, particularly in spindle formation, cytokinesis, chromosomal separation and nuclear movement. In clinic, overexpression of KSP had been used as a diagnostic marker of several cancers including bladder, stomach, breast, lung and colorectal cancers and survival rate of patients. Because cancer is a gene-associated disease with uncontrolled cell growth, targeting kinesins may develop a novel therapeutic strategy cancers. To date several KSP inhibitors have been successfully studied in clinical trials.

Kinesin superfamily involved in cancer

Most of the kinesins are plays an essential role for cancer diagnosis and prognostic marker, also some of kinesins have been implicated in a variety of disease. Kinesin superfamily (KIF) member Kinesin 4, such as KIF 4A gene is important prognostic marker for lung cancer. Taniwaki et al identified that KIF4A gene expression around 5 fold in small cell lung cancer (SCLC), however around 40% of non-small cell lung cancer (NSCLC). Also high expression of KIF4 gene detected in cervical cancer and essential role in the some cancers, such as glioma, melanoma, breast and bladder cancer. By contrast, KIF4 downregulation observed in gastric carcinoma. Overexpression of KIF14 promotes the development of breast and lung cancer. However, in case of retinoblastoma cancer, the KIF14 expressed more than two times and has been studied as a prognostic marker for disease-free survival in breast and lung cancer. Kinesin-13 family member, mitotic centromere-associated kinesin (MCAK) is participates in mitosis. MCAK overexpressed in many kinds of cancers, such as breast, colorectal cancer and glioma tissues, therefore it can act as a prognostic marker in colon cancer. Nishidate et al., reported that high-expression of MCAK leads to breast cancer development, also can be suppressed by p53. Ishikawa et al., mentioned MCAK as a marker for poor prognosis of lymph node metastasis in colorectal cancer. KIF20B (MPHOSPH1) is high expressed in bladder and colon cancer and cytokinesis defects depending by downregulation of KIF20B. Wang et al., reported that KIF2A strongly expressed in metastasis of squamous cell carcinoma of the tongue (SCCOT) and lymph node metastasis. KIF18 kinesins have been shown important role in chromosome congression. Mitotic kinesin KIF18 was found overexpressed in colorectal and breast cancer. It is associated with tumour grade metastasis. Up-regulation of mitotic kinesin-like motor protein (MKLP)1
Table 1. Kinesin subfamily protein associated tumorigenesis and function

<table>
<thead>
<tr>
<th>Kinesin</th>
<th>Family</th>
<th>Structure</th>
<th>Gene mapping</th>
<th>Relation with tumor</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIF5B</td>
<td>Kinesin-1</td>
<td>Heterotetramer</td>
<td>10p11.22</td>
<td>Bladder cancer, stomach cancer, skin and breast cancer</td>
<td>Translocation of meiotic spindle to the oocyte cortex in C. elegans meiosis and a variety of viruses to allow for their replication within the cell</td>
</tr>
<tr>
<td>KIF3A, KIF3B</td>
<td>Kinesin-2</td>
<td>Hetero-and homodimer</td>
<td>5q31.1</td>
<td>Breast cancer and renal cell carcinoma</td>
<td>Motor protein for membrane organelle transport. Dominant negative mutant result in aneuploidy and multipolar spindles</td>
</tr>
<tr>
<td>KIF1B</td>
<td>Kinesin-3</td>
<td>Dimer</td>
<td>20q11.21</td>
<td>Metastasis of nervous system tumor</td>
<td>Motor protein for carrying of mitochondria, and implicated in late stage cytokinesis</td>
</tr>
<tr>
<td>KIF14</td>
<td>Kinesin-3</td>
<td>Dimer</td>
<td>1q32.2</td>
<td>Breast cancer, ovarian cancer, and lung cancer</td>
<td>Implicated in late stage cytokinesis</td>
</tr>
<tr>
<td>KIF4A</td>
<td>Kinesin-4</td>
<td>Not confirmed</td>
<td>Xq13.1</td>
<td>Cervical cancer and non-small-cell lung cancer</td>
<td>Cytokinesis, chromosome congression and spindly assembly</td>
</tr>
<tr>
<td>KIF7</td>
<td>Kinesin-4</td>
<td>Not confirmed</td>
<td>15q26.1</td>
<td>Metastasis of multiple cancers</td>
<td>Hedgehog signaling and spindle assembly</td>
</tr>
<tr>
<td>EgS / KIF11</td>
<td>Kinesin-5</td>
<td>Bipolar tetramer</td>
<td>10q24.1</td>
<td>Chronic Myeloid Leukemia, and pancreatic cancer</td>
<td>Spindle elongation, spindle assembly and chromosome congression</td>
</tr>
<tr>
<td>MPHOSPH1 / KIF20B</td>
<td>Kinesin-6</td>
<td>Dimer</td>
<td>15q23</td>
<td>Bladder cancer and colon cancer</td>
<td>Spindle elongation, spindle assembly and regulation of midzone assembly</td>
</tr>
<tr>
<td>MKLP1 / KIF23</td>
<td>Kinesin-6</td>
<td>Dimer</td>
<td>15q23</td>
<td>Glioma</td>
<td>Spindle assembly, midbody formation cytokinesis and spindle elongation</td>
</tr>
<tr>
<td>MKLP2 / KIF20A</td>
<td>Kinesin-6</td>
<td>Dimer</td>
<td>5q31.2</td>
<td>Pancreatic cancer and gastric cancer</td>
<td>Spindle assembly, midbody formation cytokinesis and spindle elongation</td>
</tr>
<tr>
<td>CENP-E / KIF10</td>
<td>Kinesin-7</td>
<td>Dimer</td>
<td>4q24-q25</td>
<td>Hepatocellular carcinoma and Breast cancer</td>
<td>Chromosome congression and alignment</td>
</tr>
<tr>
<td>Kif18</td>
<td>Kinesin-8</td>
<td>Not confirmed</td>
<td>11p14.1</td>
<td>Colon cancer, and metastasis of breast cancer</td>
<td>Chromosome congression and alignment and central spindle dynamics</td>
</tr>
<tr>
<td>Kid</td>
<td>Kinesin-10</td>
<td>Monomer</td>
<td>16q11.2</td>
<td>Unknown</td>
<td>Chromosome congression, meiotic chromosome positioning</td>
</tr>
<tr>
<td>MCAK / KIF2C</td>
<td>Kinesin-13</td>
<td>Homodimer</td>
<td>1p34.1</td>
<td>Taxol resistance of tumor cells, colon cancer, gastric cancer and breast cancer</td>
<td>Chromosome congresson alignment and k-fiber turnover</td>
</tr>
<tr>
<td>KIF2A</td>
<td>Kinesin-13</td>
<td>Homodimer</td>
<td>Unknown</td>
<td>Squamous cell carcinoma of the tongue</td>
<td>Microtubule minus end-depolymerising motor crucial for bipolar spindle formation</td>
</tr>
<tr>
<td>HSET / KIF1</td>
<td>Kinesin-14</td>
<td>Dimer</td>
<td>6p21.3</td>
<td>Brain metastasis and Lung cancer</td>
<td>Bipolar spindle assembly, pole focusing, regulate microtubule length and number</td>
</tr>
<tr>
<td>KIFC3</td>
<td>Kinesin-14</td>
<td>Dimer</td>
<td>Unknown</td>
<td>Docetaxel resistance in breast cancer cells and paclitaxel-resistant breast cancer cell-lines</td>
<td>Bipolar spindle assembly, cooperates with cytoplasmic dynein in Golgi positioning and integration</td>
</tr>
</tbody>
</table>

This table is adapted from the Review article of Xinran Liu et al.18

was shown NSCLC and hepatocellular carcinoma. Moreover MKLP2 high expressed in pancreatic ductal adenocarcinoma (PDAC), and inhibited the growth of gastric cancer cells. High-expression of KIFC3 in docetaxel resistance in breast cancer cells. Corson et al., investigated that KIF14 overexpression
is thus tumor-specific such as breast cancer. Also it was predicted decreased disease-free survival. Moreover, mitotic kinesin KIF14 showed genomic gain and high expressed in many cancers including ovarian cancer. Thenail B et al., investigated that expression of the KIF14 is predictive of poor prognosis in breast and lung cancer. The mitotic kinesin KIF1B mutations were detected in pheochromocytomas and neuroblastomas. Also KIF1B beta germline variant related neural crest and nonneural origin. Liu et al., reported the overexpression Eg5 in human pancreatic cancer, and high expression of Eg5 was clinicopathological parameters of pancreatic cancer. Kanehira et al., reported that MPHOSPH1 genes were significantly overexpressed in the majority of bladder cancers. In fact about KIF23 downregulated in glioma cells, so Takahash et al., suggested that KIF23 might be a novel therapeutic agent of malignant glioma. KIF20A kinesins downregulation inhibits the growth of gastric cancer, also can play an essential role in anti-cancer mechanism of genistein.

CENP-E plays an important role in the function of spindle checkpoint. Lui et al., discovered that the down expression of CENP-E in human hepatocellular carcinoma. However another researchers reported that high expression of CENP-E associated with poor prognosis in breast cancer. Kif18A is a microtubule depolymerase and plays an essential role of chromosome congregation. Overexpression of Kif18A was found in colorectal cancer and metastasis. Bie et al., established KIF2C was high expressed in glioma and as a potential independent prognostic parameter for patient with glioma. In addition Ishikawa et al., reported overexpression of MCAK has been associated with aggressive forms of carcinoma and a key prognosis of colorectal cancer.

II. KSP INHIBITORS IN IN-VITRO STUDIES

Cancer can occur when the balance between mitosis and apoptosis is imbalanced or disrupt. Previously it has been well demonstrated that KSP inhibitors lead to mitotic arrest and cell death. Kinesin-5 proteins a sensitive to battery of small molecule inhibitors that allosterically block Eg5 activity. Since its discovery, over 100 different chemical classes of allosteric inhibitors against HsEg5 have been identified in the public scientific literature. These include carbolines, quinazolines, thiazolopyrimidines, thiadiazoles, dihydropyrazoles, isoquinolines, imidazoles, and benzimidazoles. A few years ago, Mayer et al., discovered monastrol shown to inhibit the kinesin Eg5, arrested cells are characterized by monopolar spindle. This phenotype is induced through specific disruption of mitotic molecular motor kinesin Eg5 with IC50 at 14 μM. No effect on other motor proteins and tubulin. This discovery regarded as a paradigm shift in anticancer drug development.

Ispinesib (SB 715992) was the first KSP inhibitor that entered clinical trials. Ispinesib shown to inhibit cancer cell proliferation of human and murine cell lines with IC50 values of 1.2–9.5 nM. Also have been shown cytotoxic activity in tumor cell lines, including Colo201, Colo205, HT-29, M5076, Madison-109, and MX-1, with IC50 of 1.2 nM to 9.5 nM. 20 nM ispinesib caused mitotic arrest in SKOV3 ovarian tumor cells, which displayed unseparated centrosomes and monopolar mitotic spindles. It also showed favorable clinical activity with a significantly lower toxicity profile in SKOV3 human tumor xenograft models, compared to tubulin targeted drugs. In addition, it exhibited anti-proliferative activity in tumor cell lines and has been shown to be effective in several murine tumor models. To note, the clinical trial with KSP inhibitor ispinesib was rather disappointing. Another facts, Ispinesib and MK-0731 have shown antiproliferative activity in tumor cell lines and several murine tumor models.

A new generation of SB743921 exhibited five-fold increased in potency against Eg5 over ispinesib with > 40,000-fold selectivity for KSP over other kinesin. It
exhibited strong cytotoxic activity in vitro and in vivo. SB 743921 confirmed a functional mitotic spindle causing G2/M cell cycle arrest and apoptosis. SB743921 have been shown cytotoxic activity against xenograft models and cancer cell lines, such as Colo205 (complete regressions), MX-1, SKOV3, MV522 and P388, with IC50 of 0.2 nM to 14.4 nM. In 2009, Woessner et al., reported a thiazole derivative ARRY-5220 demonstrated potent anti-proliferative activity in epithelial ovarian cancer cells.

KSP inhibition by ARRY-520 results in various beneficial effects against cancer development. The rectification of chromosome segregation may be activated via the spindle assembly checkpoint. It may also result in the interruption of the cell cycle during mitotic phase, which may then cause cell death to actively-dividing cells. Moreover, it does not cause peripheral neuropathy, a disease typically associated with tubulin-targeting agents, since KSP does not participate in events post mitosis. ARRY-520 showed beneficial inhibitory activity against several cell lines (HT-29, HCT-116, A2780, K562 and HCT-15). Previous studies demonstrated that ARRY-520 blocked cell cycle in mitosis and caused apoptosis in AML cell lines. SCH 2047069 showed antitumor activity in several solid tumor xenograft models, including human ovarian carcinoma A2780, human colon carcinoma Colo-205, human glioblastoma U373, and colon carcinoma HCT-116. SCH 2047069 was also significant active in EOL-1 leukemia and DoHH2 lymphoma models and significantly extended survival of these animals.

HR22C16 is required for cell division (IC50=800±10 nm). Marcus et al, tested to combination of HR22C16A with Paclitaxel. Just few years ago, another researchers were also checked anti-proliferative effect in human lung cancer H1299 cells and human lung fibroblast WI38 cells. They demonstrated that HR22C16A showed efficacy effect on cell death and mitotic arrest in cancer cells. A new compound CPUYL064 showed great inhibitory effect against Eg5. Yang et al., reported CPUYL064 was found G2/M phase arrest and anti-tumor activity against human hepatocellular carcinoma cell line with IC50 of 100 nM.

K858 is a thiazole derivative with KSP IC50 value of 1.3 μM. K858 displayed potent inhibitory activity both in vitro against HCT116 cell line and in vivo in many xenograft models of cancer. The oral KSP inhibitor SCH 2047069 has been shown the ability to cross the blood-brain barrier. SCH 2047069 exhibited anti-tumor activity against leukemia, lymphoma, ovarian and colorectal cancers both in vitro (57 tumor cell lines) and in vivo. It could also enhance the antitumor activity in A2780 xenograft models combination with gemcitabine, vincristine and paclitaxel.

Dihydropyrrole derivative MK-0731 is a synthetic small molecule and a potent and selective KSP (IC50=2.2 nM). Furthermore, MK-0731 which displayed high efficacy anti-proliferative activity in mouse xenograft model. The discovery of a benzimidazole derivative CPUYJ039 is a novel and potent KSP inhibitor (IC50=0.04 μM) was reported in 2011. CPUYJ039 blocked cell cycle in G2/M phase and leading to cell death with the monastrol spindle phenotype in HCT116 cell line. ARQ 621 demonstrated anti-tumor activity against a wide range of human cancer cell lines in vitro, including colon, lung, endometrial, bladder, and hematologic cancer cell lines and in a number of xenografts grown in athymic mice, including pancreatic, breast, prostate, and ovarian carcinomas. Compared to ispinesib, a previously characterized Eg5 inhibitor, ARQ 621 demonstrated comparable potency and proved to be a non-DNA damaging agent.

**KSP inhibitor induces cell death**

Inhibition of KSP leads to apoptosis of several cancer cell lines as well as in vitro anti-tumor activity in human xenograft models. Leizerman et al., have demonstrated that monastrol causes mitotic arrest and caspase activated cell death (activation of caspase-8, caspase-3
Table 2. Kinesin inhibitors in in vitro studies

<table>
<thead>
<tr>
<th>Inhibitors</th>
<th>Chemical structure</th>
<th>IC50</th>
<th>Cell line type</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR22C16</td>
<td><img src="HR22C16.png" alt="Chemical structure" /></td>
<td>0.65 uM</td>
<td>Human lung cancer cell-H1299, WI3876</td>
</tr>
<tr>
<td>CPUY064</td>
<td>Not confirmed</td>
<td>100 nM</td>
<td>Hepatocellular liver carcinoma cell-HEPG277</td>
</tr>
<tr>
<td>CPUY039</td>
<td>Not confirmed</td>
<td>0.04 uM</td>
<td>Human colon carcinoma cell-HCT116</td>
</tr>
<tr>
<td>K858</td>
<td><img src="K858.png" alt="Chemical structure" /></td>
<td>1.3 uM</td>
<td>Human colon carcinoma cell-HCT116 delete cell line, human ovarian cancer cell A2780</td>
</tr>
<tr>
<td>SCH2047069</td>
<td><img src="SCH2047069.png" alt="Chemical structure" /></td>
<td>Human colon carcinoma cell-HCT116 delete cell line, human ovarian carcinoma cell-A2780, human teratocarcinoma cell-PA-1</td>
<td></td>
</tr>
<tr>
<td>CF3-STLC</td>
<td><img src="CF3-STLC.png" alt="Chemical structure" /></td>
<td>140 nM</td>
<td>Human CML cell-K562, Human adenocarcinoma cell-HeLa</td>
</tr>
</tbody>
</table>

Vijapurkar et al., further elucidated the cellular responses following monastrol-induced mitotic arrest. They suggest that the cellular responses induced by monastrol that are correlated with overexpression of BclXL, the antiapoptotic Bcl-2 family protein. Overexpression of BclXL provides a protective mechanism, and its depletion rescues the apoptotic response to monastrol. Liu et al., observed that monastrol inhibitor arrested mitosis, induced cell death, and overexpressed Hsp70 (heat shock protein) in human multiple myeloma cells. ARRY-520 treated Type II EOC cells exhibited a significantly increased caspase family such as caspases-8, 9, 3 and decreased of XIAP. Caspase-2 activation leads to involvement of the mitochondria. In addition, Tunquist et al., showed that ARRY-520 treated in human multiple myeloma NCI H929 cells observed overexpressed cleaved-PARP during mitotic arrest, and decreased of the antiapoptotic protein myeloid cell leukemia 1 (Mcl-1). Kinesin-5 in HL60 cells...
showed intrinsic apoptosis during mitotic arrest with mitochondrial dysfunction such as loss of mitochondrial membrane potential and upstream event of MOMP. Furthermore, Shimizu et al., reported that KSP inhibitor CF3-STLC induced mitotic arrest with the monoastral spindles, and cell death with cleavage of PARP-1, caspase-3, and 4E-BP1. Rather Ogo et al., reported same result in HeLa cell. Recently, Basso et al., found that HT-29 cells with oral KSP inhibitor SCH 2047069 led to mitotic arrest and cell death with PARP cleavage. CPUYJ039 inhibited HCT116 cells proliferation, and G2/M cell-cycle arrest with characteristic monoastral spindles. Also showed that cell death with an increase of the Bax/Bcl-2 ratio in HCT116 cells. However Tao et al., demonstrated that apoptosis after prolonged mitotic arrest with activated pro-apoptotic protein Bax. The KSP-IA, a dihydropyrrole small molecule arrests cells in mitosis and induces apoptosis by caspase-dependent death. Moreover, KSP-IA was able to induce apoptotic cell death in a p53-independent manner, suggesting that KSP inhibitors could be proved active in p53-deficient tumors.

Orth et al., investigated that prolonged mitotic arrest activated the intrinsic apoptotic pathway. That activates p53 induction after slippage with mitochondrial dysfunction and caspase activated DNAse, causing limited DNA damage in human cancer cells. Hwang et al., showed that KSP inhibitor HR22C16 sensitized in H1299 cells to TRAIL-induced cell death by down-regulating XIAP, survivin and Bcl-2 apoptotic proteins and the activity of NF-κB. Recently, Yin et al., demonstrated that SB743921 treatment suppresses the ERK and Akt activity in CML cells.

III. KSP INHIBITORS IN CLINICAL DEVELOPMENT

In fact, a lot of new KSP inhibitors have been identified in recent years. Some of the inhibitors have already been studied in phase I or Phase II clinical trials and proved to have shown anti-proliferative effects in several types of cancers. KSP inhibitors have been successful when used as a monotherapy. The Ispinesib (SB715992) was the first KSP inhibitor to enter clinical trials. At present, it represents the most advanced and best studied KSP inhibitor. Phase I studies of ispinesib in patients with solid tumors have been completed. Generally, ispinesib was well-tolerated with no indications of neurotoxicity. The most common adverse effects were neutropenia, fatigue, anemia, leukopenia, thrombocytopenia, diarrhea, nausea, and vomiting. The most promising results have been observed in patients with advanced or metastatic breast cancer. Recently, outcomes from the phase II trial of ispinesib in 15 patients with metastatic hepatocellular carcinoma were published. Similar results were obtained from the phase II study in patients with melanoma. Other preliminary reports of ispinesib in metastatic squamous cell carcinoma of the head and neck, colorectal cancer, ovarian cancer, and renal cell carcinoma have not indicated significant response rates. Despite some promising results the outcomes from the first clinical trials of ispinesib are rather disappointing. It is known that ispinesib resistance, observed in some clinical trials, may be due to multidrug resistance. Taken together, clinical trials evaluating the efficacy and safety of KSP inhibitors, both as single and in combination with other agents, are currently ongoing. Second-generation SB743921 is now in the clinic use. SB743921, a derivative of ispinesib, is 5-fold more potent against KSP ATPase activity and it is another promising KSP inhibitor from Cytokinetics. SB743921 exhibited five-fold increase in potency against KSP over ispinesib with > 40,000-fold and is entered in a phase I/II clinical trial in non-Hodgkin’s lymphoma. Now its undergoing Phase I clinical study. SB743921 showed response in some patients and the major dose limiting toxicity was marrow suppression, in
Table 3. Kinesin inhibitors in Clinical development

<table>
<thead>
<tr>
<th>Inhibitors</th>
<th>Chemical structure</th>
<th>IC_{50}</th>
<th>Clinical trial</th>
<th>Type of cancers</th>
<th>Side effects</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ispinesib</td>
<td><img src="image1" alt="Chemical structure" /></td>
<td>1.7 nM</td>
<td>II</td>
<td>Advanced or metastatic breast cancer\textsuperscript{117}</td>
<td>Neutropenia</td>
<td>MerckCo</td>
</tr>
<tr>
<td>Ispinesib in combination with docetaxel</td>
<td><img src="image2" alt="Chemical structure" /></td>
<td></td>
<td></td>
<td>Advanced solid tumors\textsuperscript{118}</td>
<td>Prolonged neutropenia</td>
<td></td>
</tr>
<tr>
<td>SB743921</td>
<td><img src="image3" alt="Chemical structure" /></td>
<td>0.1 nM</td>
<td>I/II</td>
<td>Advanced solid tumors or replaced/refractory lymphoma\textsuperscript{119}</td>
<td>Dose-dependent neutropenia</td>
<td>Cyto-kinetics</td>
</tr>
<tr>
<td>MK-0731</td>
<td><img src="image4" alt="Chemical structure" /></td>
<td>2.2 nM</td>
<td>I</td>
<td>Advanced solid tumors\textsuperscript{111}</td>
<td>Myelosuppression</td>
<td>MerckCo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Taxane-Refractory cancer\textsuperscript{68}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZD4877</td>
<td><img src="image5" alt="Chemical structure" /></td>
<td>5 nM</td>
<td>II</td>
<td>Recurrent or refractory acute myeloid leukemia\textsuperscript{109}</td>
<td>Dose-related neutropenia, Hyperbilirubinemia, stomatitis, palmar-plantar erythrodysesthesia</td>
<td>Astra-zeneca</td>
</tr>
<tr>
<td>ARRY-520</td>
<td><img src="image6" alt="Chemical structure" /></td>
<td>6 nM</td>
<td>II</td>
<td>Advanced myeloid leukemia\textsuperscript{108}</td>
<td>Neutropenia, Myelosuppression</td>
<td>Array Bio-Pharma</td>
</tr>
</tbody>
</table>

Particular neutropenia.\textsuperscript{62} MK-0731 is a dihydropyrrole derivative developed by Merck and ARRY-520 is a thiazole derivative from Array Pharmaceuticals. MK-0731 (Merck) progressed in clinical development has
Table 3. Kinesin inhibitors in Clinical development

<table>
<thead>
<tr>
<th>Inhibitors</th>
<th>Chemical structure</th>
<th>IC50</th>
<th>Clinical trial</th>
<th>Type of cancers</th>
<th>Side effects</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARQ621</td>
<td><img src="image" alt="ARQ621 Structure" /></td>
<td>1.8 nM</td>
<td>I</td>
<td>Solid tumors and hematologic disorders$^{120}$</td>
<td>Neutropenia, anemia, fatigue and nausea</td>
<td>ArQule</td>
</tr>
<tr>
<td>LY2523355</td>
<td><img src="image" alt="LY2523355 Structure" /></td>
<td>7 nM</td>
<td>I</td>
<td>Advanced solid tumors$^{113}$</td>
<td>Neutropenia, leukopenia, diarrhea and mucositis</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>4SC-205</td>
<td>Not confirmed</td>
<td>3 nM</td>
<td>I</td>
<td>Colon cancer, Malignant lymphoma$^{116}$</td>
<td>Neutropenia</td>
<td>4SC</td>
</tr>
</tbody>
</table>

shown anti-proliferative activity in several tumor cell lines and significant efficacy in some murine tumor models. MK-0731 was tolerated when administrated in 17 mg/m^2 dose.$^{62}$ In addition, ARRY-520 (Array Biofarma) is currently in a phase I trial and phase II in advanced cancer patients and has shown remarkable efficacy in preclinical models of human solid tumors and human leukemia showed only limited response.$^{108}$

The AZD4877,$^{109,110}$ MK-0731$^{111}$ and EMD544085 as novel KSP single agent in melanoma$^{105}$ and clear-cell renal cell cancer.$^{39,112}$ However the final clinical results have not been reported. Therapy with ARQ621 appears well tolerated, with no dose-limiting toxicity observed at doses and frequencies much higher than those achieved with the leading Eg5 inhibitors of comparable potencies. Wakui et al., studied effect of LY2523355 in Japanese patients with advanced solid tumors. Who had grade 4 neutropenia or grade 3 febrile neutropenia, they used G-CSF. Also observed that no objective tumor responses.$^{113}$ The most frequent side effects were neutropenia, leukopenia, diarrhea, rash and mucositis.$^{114}$ 4SC-205 is now being investigated in a clinical phase 1, in patients with solid tumors or malignant lymphomas.$^{115}$ The compound exhibits dose-proportional pharmacokinetics with t_1/2 $\sim$10. Dose limiting toxicities include increased neutropenia.$^{116}$ Table 3 shown KSP inhibitors in clinical development and some side effects.

**Drug resistance for KSP inhibitors**

Drug resistance is common cause of treatment failure for cancer. Resistance to chemotherapeutic drugs is a big problem of treatment of patients with cancer that encumbers the efficacy of cytostatic drugs.$^{18}$ Which may be caused through the expression of efflux pumps such as P-gp$^{121,122}$ and several KIF proteins, such as KIFC3 and MCAK, might be lead to drug resistance.$^{54,57}$

The way to target KIF combined with chemotherapy can provide a classic manner to treat cancer, when serious
chemotherapeutic drug resistance exist then cancer cells' anti-apoptotic proteins can also generate drug resistance. Preclinical studies mentioned that Ispinesib is predicted to be a substrate for drug resistance. A KSP inhibitor developed by Merck, MK-0731, has been modified and avoided to be the substrate for P-glycoprotein mediated efflux, giving it more potential for entering clinical trials. Binding pocket mutation is another origin of drug resistance in cancers. An alteration of the L5 pocket of KSP could offset the action of APT non-competitive inhibitors binding to it. Prior to patient use, this mutation could be measured by structural biomarkers predictive of drug potency.

Side effects of KSP inhibitors

Neutropenia is the most common side effects of KSP inhibitors and along other side effects. Because the doubling time of granulocyte precursors is very short [17 hours for myeloblasts, 63 hours for promyelocytes, and 55 hours for myelocytes]. Thus, reversible neutropenia would be expected of an agent targeting a mitotic kinase or KSP, because at any one time ~25% of bone marrow neutrophils are undergoing mitosis. Other common side effects are anemia, fatigue, nausea/vomiting and leukopenia, overexpression of aspartate or alanine aminotransferase, hyperbilirubinemia and hyponatremia. Clinical studies for AZD4877 and MK0731 have been carried out because of leukopenia, elevation of aspartate and alanine aminotransferase, hyperbilirubinemia and hyponatremia. Some cases, no neurotoxicity observed in trials. Because some KSP is expressed at low levels in the adult nervous system in rodent and KSP inhibitors do not target microtubules.

Conclusions and Perspectives

Going back to 1985 when the first kinesin was discovered with 14 kinesin family types, each was identified that contains various proteins. Alteration of these protein expression and functions leads to human disease, including tumorgenesis and progression. KSP inhibitors are attractive and promising anti-proliferative agents for cancer chemotherapy, such as some solid tumors and hematologic malignancies. Compared with other antimitotics, KSP inhibitors have shown potent anti-proliferative effects without causing significant neuropathy. The challenge for clinical development of KSP inhibitors observed drug resistance and side effects. However novel KSP inhibitors and combination therapy is still attractive field. Another unanswered question is how do KSP inhibitors induce mitochondria mediated cell death? Although it is suggested that KSP inhibition enhances caspase mediated apoptotic cell death but the underlying mechanism is not yet clear. These concerns are needed to be answered in the future studies. Besides blocking tumor cell proliferation, kinesin inhibitors showed potential to block angiogenesis which further suggest novel mechanism of kinesin inhibitors in pathophysiological modulation of vascular forming and functions.

ACKNOWLEDGEMENT

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0920040) and Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0020224).

REFERENCES

2. Rowinsky EK, Chaudhry V, Comblath DR, Donehower RC.


